Gresham, OR, January 8, 2013/Cyn3rgy Research – Cyn3rgy Research in Gresham, OR announced today that they are taking part in the largest-ever global clinical research program in children ages 6 to 12 with autism, Asperger’s Disorder and Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). This Phase II ConnectMe clinical research program, which is currently enrolling participants in the Gresham and Portland areas, is evaluating the safety, tolerability and efficacy of the investigational drug, memantine, on social interaction and communication.
Jan 9, 2013